George Thomas Budd
George Thomas Budd
Unknown affiliation
Verified email at
Cited by
Cited by
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli, GT Budd, MJ Ellis, A Stopeck, J Matera, MC Miller, ...
New England Journal of Medicine 351 (8), 781-791, 2004
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer
M Cristofanilli, DF Hayes, GT Budd, MJ Ellis, A Stopeck, JM Reuben, ...
Journal of clinical oncology 23 (7), 1420-1430, 2005
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival
DF Hayes, M Cristofanilli, GT Budd, MJ Ellis, A Stopeck, MC Miller, ...
Clinical Cancer Research 12 (14), 4218-4224, 2006
Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer
GT Budd, M Cristofanilli, MJ Ellis, A Stopeck, E Borden, MC Miller, ...
Clinical Cancer Research 12 (21), 6403-6409, 2006
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer
SE Jones, J Erban, B Overmoyer, GT Budd, L Hutchins, E Lower, ...
Journal of Clinical Oncology 23 (24), 5542-5551, 2005
Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study
S Seicean, A Seicean, JC Plana, GT Budd, TH Marwick
Journal of the American College of Cardiology 60 (23), 2384-2390, 2012
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR
DG Hicks, SM Short, NL Prescott, SM Tarr, KA Coleman, BJ Yoder, ...
The American journal of surgical pathology 30 (9), 1097-1104, 2006
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.
CW Taylor, S Green, WS Dalton, S Martino, D Rector, JN Ingle, NJ Robert, ...
Journal of Clinical Oncology 16 (3), 994-999, 1998
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA. 27—a randomized controlled phase III trial
PE Goss, JN Ingle, KI Pritchard, MJ Ellis, GW Sledge, GT Budd, ...
Journal of clinical oncology 31 (11), 1398, 2013
Estrogen receptor mutations in tamoxifen-resistant breast cancer
PS Karnik, S Kulkarni, XP Liu, GT Budd, RM Bukowski
Cancer research 54 (2), 349-353, 1994
Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of …
MJ Ellis, VJ Suman, J Hoog, R Goncalves, S Sanati, CJ Creighton, ...
Journal of Clinical Oncology 35 (10), 1061, 2017
Novel prognostic immunohistochemical biomarker panel for estrogen receptor–positive breast cancer
BZ Ring, RS Seitz, R Beck, WJ Shasteen, SM Tarr, MCU Cheang, ...
Journal of Clinical Oncology 24 (19), 3039-3047, 2006
Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure
S Seicean, A Seicean, N Alan, JC Plana, GT Budd, TH Marwick
Circulation: Heart Failure 6 (3), 420-426, 2013
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre …
WD Tap, Z Papai, BA Van Tine, S Attia, KN Ganjoo, RL Jones, S Schuetze, ...
The lancet oncology 18 (8), 1089-1103, 2017
NCCN guidelines insights: bone cancer, version 2.2017
JS Biermann, W Chow, DR Reed, D Lucas, DR Adkins, M Agulnik, ...
Journal of the National Comprehensive Cancer Network 15 (2), 155-167, 2017
The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy
Y Zhang, AM Sieuwerts, M McGreevy, G Casey, T Cufer, A Paradiso, ...
Breast cancer research and treatment 116 (2), 303-309, 2009
Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial.
RL Miller, RM Bukowski, GT Budd, J Purvis, JK Weick, K Shepard, ...
Journal of Clinical Oncology 6 (5), 880-888, 1988
Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma
RM Bukowski, W Sharfman, S Murthy, P Rayman, R Tubbs, J Alexander, ...
Cancer research 51 (16), 4199-4205, 1991
Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis
R Van Stolk, G Stoner, WL Hayton, K Chan, B DeYoung, L Kresty, ...
Clinical cancer research 6 (1), 78-89, 2000
Management of angiosarcoma
GT Budd
Current oncology reports 4 (6), 515-519, 2002
The system can't perform the operation now. Try again later.
Articles 1–20